Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Ill-defined disorder? 380 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 380 reports of Ill-defined disorder have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.3% of all adverse event reports for EVOLOCUMAB.

380
Reports of Ill-defined disorder with EVOLOCUMAB
0.3%
of all EVOLOCUMAB reports
7
Deaths
59
Hospitalizations

How Dangerous Is Ill-defined disorder From EVOLOCUMAB?

Of the 380 reports, 7 (1.8%) resulted in death, 59 (15.5%) required hospitalization, and 6 (1.6%) were considered life-threatening.

Is Ill-defined disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 380 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Ill-defined disorder?

ACETAMINOPHEN\OXYCODONE (9,780) ACETAMINOPHEN\HYDROCODONE (6,159) TOCILIZUMAB (4,411) RITUXIMAB (4,220) ETANERCEPT (4,202) METHOTREXATE (4,063) ABATACEPT (3,630) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (3,600) LEFLUNOMIDE (3,570) CERTOLIZUMAB PEGOL (3,273)

Which EVOLOCUMAB Alternatives Have Lower Ill-defined disorder Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Ill-defined disorder Reports All Drugs Causing Ill-defined disorder EVOLOCUMAB Demographics